Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-India's Omicron cases mild, vaccine boosters not a priority -government

Fri, 10th Dec 2021 12:53

(Adds details)

NEW DELHI, Dec 10 (Reuters) - India has detected 25 cases of
the emergent Omicron variant of the coronavirus and all have
shown mild symptoms, the health ministry said on Friday, adding
that there was no immediate plan to authorise vaccine boosters.

Vaccine supplies have surged in India in recent months
thanks to the Serum Institute of India (SII), which now plans to
halve the monthly output of its version of the AstraZeneca
vaccine as demand has crashed.

The SII and other Indian drugmakers such as Dr. Reddy's
Laboratories, which distributes Russia's Sputnik
vaccine, have lobbied the government https://www.reuters.com/world/india/indian-vaccine-makers-bank-boosters-demand-crashes-2021-12-08
to approve booster shots in a bid to lift sales.

Senior health official Vinod Kumar Paul told a news briefing
that government experts were studying data on boosters but "our
emphatic view...is to (first) cover every adult with (just) the
primary two doses."

The government has said this target can be achieved by
January.

India has not considered authorising booster doses yet as
many in the country have been naturally infected and the
government believes two vaccine doses offer sufficient
protection for now, three informed sources told Reuters late
last month.

Around 87% of India's adults, estimated at 939 million
people, have received at least one dose of a vaccine and 54% of
them have received the full two. Inoculations for those under
the age of 18 years have not started.

Paul spoke after the World Health Organization recommended
that people with compromised immunity or those who received an
inactivated vaccine should receive a booster.

Inactivated vaccines, which use killed or inactivated
coronavirus to induce immunity, is made by India's Bharat
Biotech and some Chinese companies.

At 144 million doses, Bharat Biotech's Covaxin accounts for
about 11% of the total vaccine doses administered in India. Many
Indian healthcare workers received Covaxin early this year and
some experts say they should soon be allowed to take a booster.

India's daily new COVID-19 cases have hovered around 10,000
for the past few weeks, taking the total to 34.67 million, more
than 474,000 of whom have died.

Most contracted the Delta variant, though Omicron has spread
to five states after India's first two cases were reported on
Dec. 2. "All detected cases have mild symptoms," a health
ministry statement said.
(Reporting by Krishna N. Das, Rama Venkat and Sumit Khanna;
Editing by Mark Heinrich)

More News
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.